Influenza A H1N1 vaccine - Bharat Biotech

Drug Profile

Influenza A H1N1 vaccine - Bharat Biotech

Alternative Names: Cell cultured inactivated BBIL H1N1 vaccine; HN-VAC; HNVAC; Influenza A/H1N1 adjuvant vaccine (HN-VAC) - Bharat Biotech

Latest Information Update: 14 Jul 2011

Price : $50

At a glance

  • Originator Bharat Biotech
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H1N1 subtype

Most Recent Events

  • 18 Oct 2010 Launched for Influenza-A virus H1N1 subtype in India (IM); first global launch
  • 21 Jul 2010 Bharat Biotech completes enrolment in its phase II/III trial for Influenza A-virus H1N1 subtype (in volunteers) in India
  • 19 Jan 2010 Phase-I clinical trials in Influenza-A virus H1N1 subtype (prevention) in India (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top